Please enable JS

Our Partnerships

OUR PARTNERING PHILOSOPHY

At CRISPR Therapeutics, we view strategic partnerships as a core component of our strategy to allow us to access capabilities and resources in support of our therapeutic programs.  CRISPR Therapeutics is interested in partnering with biopharma companies, academic centers, universities and other relevant organizations. 

To date, CRISPR has established two strategic partnerships – a research collaboration with Vertex Pharmaceuticals Inc. and a joint venture with Bayer AG, to develop gene-editing based therapeutics in specific disease areas.  Additionally, CRISPR has developed a number of other relationships with academic labs to access technologies to improve the CRISPR platform and support the advancement of our programs.

For inquiries, please contact us at BD@CrisprTx.com.

Our Current Partnerships

logo: Vertex
Vertex
www.vrtx.com


Summary
CRISPR Therapeutics has a four-year strategic research collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX) to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. As part of the collaboration, Vertex made an up-front commitment of $105 million to CRISPR, including $75 million in cash and a $30 million equity investment. CRISPR is also eligible to receive future development, regulatory and sales milestones and royalty payments on future sales.

The partnership will enable CRISPR Therapeutics to conduct discovery activities in multiple therapeutics areas with the related expenses fully funded by Vertex. Vertex and CRISPR will focus their initial gene editing research on discovering treatments to address the mutations and genes known to cause and contribute to cystic fibrosis and sickle cell disease. Vertex and CRISPR will also evaluate a specified number of other genetic targets as part of the collaboration. Specifically for hemoglobinopathies, including treatments for sickle cell disease, Vertex and CRISPR will equally share all research and development costs and sales, with CRISPR Therapeutics leading commercialization efforts in the U.S. Vertex will have exclusive rights to license up to six new CRISPR/Cas9-based treatments that emerge from the collaboration.

About Vertex
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Vertex is headquartered in Cambridge, Massachusetts and has research and development sites and commercial offices in the United States, Europe, Canada and Australia.

Please read the press release for more details.

 

logo: Bayer
Bayer
www.bayer.com



logo: Casebia
Casebia
www.casebia.com




Summary

CRISPR Therapeutics and Bayer AG established a joint venture (JV) designed to bring breakthrough therapies to patients suffering from such serious conditions as blood disorders, blindness and congenital heart disease.

CRISPR has 50 percent ownership in the JV, which will be fueled by $300 million in research and development funding from Bayer over the next five years.  Bayer also acquired a minority stake in CRISPR Therapeutics for an additional $35 million investment.

The JV will be based in London with operations in Cambridge, Massachusetts.   Dr. Axel Bouchon, Head of the Bayer LifeScience Center, will serve as interim CEO.  Dr. Rodger Novak, CEO and co-founder of CRISPR Therapeutics, will serve as interim chairman of the JV board of directors.

CRISPR will contribute its proprietary CRISPR/Cas9 gene-editing technology, while Bayer will bring its protein engineering expertise and deep experience in the targeted disease areas to bear in the JV.

CRISPR Therapeutics will have full access to the intellectual property created by the JV at no cost.  Newly created know-how from the collaboration around the CRISPR/Cas9 system beyond the three disease areas, will be exclusively made available to CRISPR Therapeutics for human-use, and to Bayer for non-human use, such as agricultural applications.

This is the first strategic partnership to make a substantial investment in the development of target delivery systems – all with the goal of developing systemic in vivo CRISPR/Cas9 gene editing technology applications for patients.

About Bayer
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed around 119,000 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. 

Please read the press release for more details.



logo: AnagenesisAnagenesis
www.anagenesis-biotechnology.com

Summary
CRISPR Therapeutics and Anagenesis Biotechnologies established a strategic in-licensing and collaboration agreement, which grants CRISPR Therapeutics exclusive worldwide license to Anagenesis’ proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology for cell therapy for all human muscle diseases. The P2MC technology allows for the efficient, reproducible and chemically defined differentiation of pluripotent cells into skeletal muscle stem cells, also known as satellite cells. The agreement will support the advancement of CRISPR-based cellular therapies for the treatment of musculoskeletal diseases. Initial research will focus on Duchenne Muscular Dystrophy (DMD) and forms an important building block in support of the broader research strategy within DMD and other musculoskeletal diseases.

Anagenesis’ proprietary P2MC technology was developed with the support of AFM-telethon, INSERM-Transfert, CNRS and Université de Strasbourg. This technology, in combination with CRISPR/Cas9 gene editing, has the potential to yield important new treatments for boys with DMD, and for patients with other muscle disorders. Bringing together the CRISPR gene editing platform with the P2MC technology enables the development of ex vivo therapeutic approaches for the treatment of DMD using muscle satellite stem cells.

About Anagenesis Biotechnologies

Anagenesis Biotechnologies is a private company developing new treatments against muscle diseases (genetic such as DMD and chronic such as sarcopenia and cachexia). The company was cofounded by Dr. Olivier Pourquié, a worldwide key opinion leader in the field of musculoskeletal development and stem cells. Olivier Pourquié is a Professor at Harvard Medical School and the Brigham and Women’s Hospital and a member of the Harvard Stem Cell Institute. Anagenesis Biotechnologies is backed by a solid, experienced team led by its President & CEO, Dr. Jean-Yves Bonnefoy, coming from the Pharma & Biotech industry. Anagenesis Biotechnologies in Illkirch, France, is now focusing on HTS and HCS screens, while its newly formed US-subsidiary in Boston, MA, Anagenesis Biotherapies Inc., is developing the cell therapy approaches.

Please read the press release for more details.